Pemphigus

Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Full text  Abstract

Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. Abstract

Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1. Abstract

Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Abstract

1. Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Full text  Abstract

2. Hsu YM, Fang HY, Lin CL, et al. The risk of depression in patients with pemphigus: a nationwide cohort study in Taiwan. Int J Environ Res Public Health. 2020 Mar 17;17(6):1983.Full text  Abstract

3. Sajda T, Sinha AA. Autoantibody signaling in pemphigus vulgaris: development of an integrated model. Front Immunol. 2018;9:692.Full text  Abstract

4. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993 Jul;11(3):473-81. Abstract

5. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. Abstract

6. Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980 Sep;116(9):1035-7. Abstract

7. Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019 Jul 29;94(3):264-78.Full text  Abstract

8. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015 May;307(4):291-8.Full text  Abstract

9. Wertenteil S, Garg A, Strunk A, et al. Prevalence Estimates for Pemphigus in the United States: A Sex- and Age-Adjusted Population Analysis. JAMA Dermatol. 2019 May 1;155(5):627-629.Full text  Abstract

10. Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol. 1996 Jul;107(1):68-75. Abstract

11. Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015 Dec;173(6):1447-52. Abstract

12. Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012 Oct;148(10):1165-72.Full text  Abstract

13. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993 Jul;11(3):429-52. Abstract

14. Crosby DL, Diaz LA. Endemic pemphigus foliaceus. Fogo selvagem. Dermatol Clin. 1993 Jul;11(3):453-62. Abstract

15. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990 Dec 20;323(25):1729-35.Full text  Abstract

16. Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. J Invest Dermatol. 1989;92:4-12. Abstract

17. Vernal S, Pepinelli M, Casanova C, et al. Insights into the epidemiological link between biting flies and pemphigus foliaceus in southeastern Brazil. Acta Trop. 2017 Dec;176:455-62. Abstract

18. Aoki V, Millikan RC, Diaz LA, et al. Environmental risk factors in pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004;9:34-40. Abstract

19. Qian Y, Jeong JS, Maldonado M, et al. Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol. 2012 Aug 15;189(4):1535-9.Full text  Abstract

20. Peng B, Temple BR, Yang J, et al. Identification of a primary antigenic target of epitope spreading in endemic pemphigus foliaceus. J Autoimmun. 2021 Jan;116:102561. Abstract

21. Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000 Aug;143(2):343-8. Abstract

22. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997 Aug;40(8):1374-82. Abstract

23. Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006 Nov;39(7):617-30. Abstract

24. Bordenave K, Griffith J, Hordes SM, et al. The historical and geomedical immunogenetics of pemphigus among the descendants of Sephardic Jews in New Mexico. Arch Dermatol. 2001 Jun;137(6):825-6. Abstract

25. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. Jul-Aug 2011;29(4):455-7. Abstract

26. Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1. Abstract

27. Raneses E, McGinley Simpson M, Rosenberg A, et al. A retrospective review of autoimmune bullous disease antibody positivity before clinical symptoms. J Am Acad Dermatol. 2021 Feb 4;S0190-9622(21)00315-7. Abstract

28. Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017 Nov;177(5):1170-1201.Full text  Abstract

29. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999 May 6;340(18):1406-10. Abstract

30. Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. 2007 Jan;56(1):153-9. Abstract

31. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Abstract

32. Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015 Nov;95(8):928-32.Full text  Abstract

33. Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol. 2018 Jan;54:131-8. Abstract

34. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019 Sep 7;394(10201):882-94. Abstract

35. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2014 Dec;150(12):1331-5. Abstract

36. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006 Nov;142(11):1447-54. Abstract

37. Kawashita MY, Tsai K, Aoiki V, et al. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol. 2005 Jul;32(7):574-80. Abstract

38. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007 Aug 9;357(6):545-52.Full text  Abstract

39. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26;355(17):1772-9.Full text  Abstract

40. Gurcan HM, Jeph S, Ahmed AR, et al. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 2010;11(5):315-26. Abstract

41. Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012 Apr;166(4):844-52. Abstract

42. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011 Oct;29(4):607-12. Abstract

43. Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011 Aug;50(8):905-14. Abstract

44. Kardos M, Levine D, Gürcan HM, et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009 Nov;64(11):739-49. Abstract

45. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996 Dec;132(12):1435-9. Abstract

46. US National Library of Medicine. Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV). Jan 2021 [internet publication].Full text

47. Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1768-76. Abstract